StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report issued on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of GLMD opened at $0.31 on Friday. The business’s 50 day moving average is $0.36 and its 200 day moving average is $0.37. Galmed Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $5.47. The company has a market capitalization of $1.55 million, a PE ratio of -0.13 and a beta of 0.69.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its quarterly earnings data on Thursday, May 30th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- Overbought Stocks Explained: Should You Trade Them?
- Don’t Miss These Stock Picks for the Lumber Price Surge
- How to Calculate Inflation Rate
- NVIDIA Stock Defies Skeptics, Earns Analyst Upgrade
- What is a Stock Market Index and How Do You Use Them?
- 3 Highly Profitable Companies Set for Double-Digit Upside
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
